
Utilizing Spatial Transcriptomics to Unlock Precision Pain Therapeutics
Americas/Europe
View On DemandAPAC
View On DemandDoloromics is a seed-stage startup developing novel therapeutics to treat chronic pain. The team at Doloromics has built a proprietary computational platform to identify drug targets within the human Dorsal Root Ganglion (DRG). Through a collaboration with NanoString, the company deeply sequenced and transcriptomically profiled nociceptors to uncover moderate-to-low expressed drug targets that would typically be overlooked by traditional sequencing methods. The results demonstrated by the team illuminate the ways in which the GeoMx® Digital Spatial Profiling platform can be used to facilitate an approach to precision medicine.
Speaker

Jackson Brougher, PhD
Chief Scientific Officer, Doloromics
Jackson Brougher is the Chief Scientific Officer of Doloromics, a pain therapeutics startup located in Menlo Park, California. Jackson obtained his Ph.D. at the University of Texas at Dallas before co-founding the company in the spring of 2021. Through his tenure at the company, he has helped to develop Doloromic's computational platform, DOLOReS, into a multi-omic drug target discovery engine.